Related references
Note: Only part of the references are listed.Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
Frank Kolbinger et al.
PHARMACOLOGY & THERAPEUTICS (2022)
IgA vasculitis during secukinumab therapy
Dijana Perkovic et al.
CLINICAL RHEUMATOLOGY (2021)
Secukinumab-Induced Lupus Erythematosus A Case Report and Literature Review
Jaspreet Kaler et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2021)
Secukinumab-induced scleroderma: a case report
Nadia Elias et al.
RHEUMATOLOGY (2021)
A systematic review of eczematous eruptions in patients receiving biologic therapy
Asfandyar Mufti et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus
Tomohiro Koga et al.
FRONTIERS IN IMMUNOLOGY (2021)
The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges
Daniele Noviello et al.
FRONTIERS IN IMMUNOLOGY (2021)
Secukinumab-induced multiple lentigines in areas of resolved psoriatic plaques: A case report and literature review
Sanquan Zhang et al.
DERMATOLOGIC THERAPY (2021)
The Role of IL-17-Producing Cells in Cutaneous Fungal Infections
Yu Sawada et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Management of psoriasis as a systemic disease: what is the evidence?
N. J. Korman
BRITISH JOURNAL OF DERMATOLOGY (2020)
Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions
Sabrina Ching Tung Wong et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2020)
New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report
D. Currado et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2020)
Secukinumab-induced paradoxical hidradenitis suppurativa
Francisco J. Navarro-Trivino et al.
DERMATOLOGIC THERAPY (2020)
Secukinumab-Induced Acute Autoimmune Hemolytic Anemia
Rivas Sebastien et al.
ANNALS OF PHARMACOTHERAPY (2020)
Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction
Uwe Wollina et al.
DERMATOLOGIC THERAPY (2020)
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
G. Caldarola et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria
D. A. Sabag et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis
Masataka Satoh et al.
DERMATOLOGIC THERAPY (2020)
Secukinumab-induced subacute cutaneous lupus erythematosus
Claudio Conforti et al.
DERMATOLOGIC THERAPY (2020)
Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review
Jing-yao Liang et al.
DERMATOLOGIC THERAPY (2020)
New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature
Lula Maria Nieto-Benito et al.
CLINICAL DRUG INVESTIGATION (2020)
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Ahmed Almradi et al.
BIODRUGS (2020)
New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
Huda Nadwi et al.
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL (2020)
Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis
Clara Chelli et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Secukinumab-induced Raynaud's phenomenon: first report in the literature
Senol Kobak
THERAPEUTIC ADVANCES IN DRUG SAFETY (2020)
Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
Reetesh Bose et al.
SAGE OPEN MEDICAL CASE REPORTS (2020)
A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report
Stefano Dastoli et al.
CURRENT DRUG SAFETY (2020)
Secukinumab-induced paradoxical pustular psoriasis
S. Dogra et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2019)
Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab
Kayo Jin et al.
JOURNAL OF DERMATOLOGY (2019)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database
Laurent Arnaud et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Pseudolymphoma induced by secukinumab for treatment of chronic plaque psoriasis
William C. Cranwell et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2019)
The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
Tomohiro Koga et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition
M. Napolitano et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Systematic review and meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents
Akihiro Yamada et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?
Walter Fries et al.
CLINICAL DRUG INVESTIGATION (2019)
Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: A case of serendipity or zemblanity?
Lidia Sacchelli et al.
DERMATOLOGIC THERAPY (2019)
Occurrence of Henoch-Schonlein purpura in a patient treated with secukinumab
M. Reverte et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report
Matthew K. Smith et al.
BMC GASTROENTEROLOGY (2019)
New onset alopecia areata during secukinumab therapy
Basak Yalici Armagan et al.
DERMATOLOGIC THERAPY (2019)
Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris
M. Hayashi et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Secukinumab-Associated Crystalline Corneal Deposition
Barry Power et al.
CORNEA (2019)
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Alexander R. Moschen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Secukinumab induced Behcet's syndrome: a report of two cases
Elif Dincses et al.
OXFORD MEDICAL CASE REPORTS (2019)
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
M. Galluzzo et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2019)
Secukinumab-induced subacute-cutaneous lupus erythematosus
C. Wehrmann et al.
HAUTARZT (2018)
IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis
Emma Guttman-Yassky et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis
Yuichi Teraki et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab
D. Hoshina et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2018)
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
Jawad Bilal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
Nick Vandeghinste et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Vasculitis-What Do We Have to Know? A Review of Literature
Eran Shavit et al.
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS (2018)
Recurrent angular cheilitis after secukinumab injections
Taiyo Hitaka et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
Oral lichen planus associated with candidiasis during secukinumab treatment
Takaya Komori et al.
JOURNAL OF DERMATOLOGY (2017)
Interleukin-17A Inhibitor-induced Crohn's Disease/Behcet's Disease-like Lesions
Hisashi Shiga et al.
INFLAMMATORY BOWEL DISEASES (2017)
Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris
Ikko Kajihara et al.
JOURNAL OF DERMATOLOGY (2017)
Development of bullous pemphigoid during secukinumab treatment for psoriasis
Po-Han Ho et al.
JOURNAL OF DERMATOLOGY (2017)
Secukinumab-Induced Psoriasiform Eruption
Michael J. Sladden et al.
JAMA DERMATOLOGY (2017)
Image Gallery: Resolution of lichen striatus in a patient with coexisting chronic plaque psoriasis and vitiligo during secukinumab treatment
C-W Yang et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Adiposity induced by interleukin-17A blockade
T. Nakamura et al.
DIABETES & METABOLISM (2017)
Drug eruption caused by secukinumab
Mayu Shibata et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2017)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
EXPERT OPINION ON DRUG SAFETY (2016)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis
Olivia Leigh Quach et al.
JAMA DERMATOLOGY (2016)
IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment
Agneta Zickert et al.
BMC IMMUNOLOGY (2015)
Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity
Roba M. Talaat et al.
CYTOKINE (2015)
Growth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage
Xinyang Song et al.
IMMUNITY (2015)
Gut-Busters: IL-17 Ain't Afraid of No IL-23
Natasha Whibley et al.
IMMUNITY (2015)
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Joseph R. Maxwell et al.
IMMUNITY (2015)
Expansion of Circulating T Follicular Helper Cells in Children with Acute Henoch-Schonlein Purpura
Jue Xie et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Negative feedback on IL-23 exerted by IL-17A during pulmonary inflammation
Elin Silverpil et al.
INNATE IMMUNITY (2013)
Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics
Wim B. van den Berg et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2013)
Correlations between Psoriasis and Inflammatory Bowel Diseases
Nevena Skroza et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
Mutual Antagonism of T Cells Causing Psoriasis and Atopic Eczema
Stefanie Eyerich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Increased serum interleukin-17 and peripheral Th17 cells in children with acute Henoch-Schonlein purpura
Hsiao-Yu Jen et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2011)
Differential Roles of Interleukin-17A and-17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses
Harumichi Ishigame et al.
IMMUNITY (2009)
IL-17 and the Th17 lineage in systemic lupus erythematosus
Lee Ann Garrett-Sinha et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology
Mandy J. McGeachy et al.
NATURE IMMUNOLOGY (2007)
Claudins regulate the intestinal barrier in response to immune mediators
T Kinugasa et al.
GASTROENTEROLOGY (2000)
Share Paper
